Zymeworks (ZYME)
(Real Time Quote from BATS)
$12.52 USD
-0.08 (-0.64%)
Updated Aug 5, 2025 10:22 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZYME 12.52 -0.08(-0.64%)
Will ZYME be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Other News for ZYME
Commit To Buy Zymeworks At $7.50, Earn 26.1% Annualized Using Options
Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance
Zymeworks (ZYME) Receives FDA Green Light for New Drug Targeting Liver Cancer
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel ...
Zymeworks announces FDA clearance of IND application for ZW251